Clik here to view.
新研究比较Masimo下一代SedLine®患者状态指数(PSi)与原初Psi在麻醉期间的性能
日内瓦 (美国商业资讯) — Masimo (NASDAQ: MASI)今天发布了瑞士日内瓦召开的Euroanaesthesia 2017 上呈报的一篇摘要的发现。在该研究中，荷兰格罗宁根大学医疗中心的研究者比较了异丙酚和七氟烷麻醉患者在Masimo SedLine®...
View ArticleClik here to view.
Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that data from two Phase 1/2 clinical trials evaluating NINLARO™ (ixazomib) in patients with...
View ArticleClik here to view.
Acelity Strengthens Global Commercial Leadership; Names Ramesh Subrahmanian...
SAN ANTONIO Acelity L.P. Inc., a leading global advanced wound care company, today announced Ramesh Subrahmanian will join the company as President for the International region and member of the...
View ArticleClik here to view.
Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1...
CAMBRIDGE, Mass., OSAKA, Japan & BOTHELL, Wash. Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ECHELON-1 clinical...
View ArticleClik here to view.
Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to...
SAN DIEGO & REHOVOT, Israel & SEOUL, South Korea Today, Korea Investment Partners (KIP), DSC Investments, Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd, a clinical...
View ArticleClik here to view.
武田呈报NINLARO™ (ixazomib)用于新诊断多发性骨髓瘤患者及维持治疗的1/2期研究数据
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，两项评估NINLARO™ (ixazomib)用于新诊断多发性骨髓瘤患者的1/2期临床试验的数据将在欧洲血液学会(EHA) 2017年年会上口述呈报，时间分别是中欧夏令时6月24日星期六上午11:45 – 12和6月25日星期日上午8:15 –...
View ArticleClik here to view.
LEDを自然な光に回帰させるソウル半導体の新技術“SunLike”
韓国安山市 （ビジネスワイヤ） — LED製品および技術の世界的なイノベータのSeoul Semiconductor Co., Ltd....
View ArticleClik here to view.
武田薬品、初発多発性骨髄腫患者および維持療法でニンラーロ（イキサゾミブ）を検討する第1／2相試験のデータを発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
Groundbreaking Multi-Center Clinical Trial Confirms Low-Dose Aspirin Therapy...
LJUBLJANA, Slovenia PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the publication of the Fetal Medicine Foundation’s (FMF’s) Project “ASPRE” study...
View ArticleClik here to view.
The New SCIEX Clinical AB SCIEX TRIPLE QUAD™ 4500MD LC-MS/MS System Obtains...
SHANGHAI SCIEX Diagnostics, the in vitro diagnostics division of SCIEX, a global leader in mass spectrometry in the life sciences industry, announced today that the AB SCIEX TRIPLE QUAD™ 4500MD...
View ArticleClik here to view.
Sanpower Group Closes Acquisition of Dendreon
SEAL BEACH, Calif. Dendreon Pharmaceuticals LLC (“Dendreon”) today announced the close of a transaction in which Sanpower Group, a private Chinese conglomerate, acquired Dendreon from an affiliate...
View ArticleClik here to view.
武田薬品とシアトル・ジェネティクスが進行期ホジキンリンパ腫のフロントライン治療でアドセトリス（ブレンツキシマブ・ベドチン）を評価する第3相ECHELON-...
米マサチューセッツ州ケンブリッジ & 大阪 & 米ワシントン州ボセル （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502）とシアトル・ジェネティクス（NASDAQ:...
View ArticleClik here to view.
武田与Seattle Genetics发布ADCETRIS® (brentuximab...
马萨诸塞州剑桥、日本大阪和华盛顿州博瑟尔 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)和Seattle Genetics, Inc. (NASDAQ: SGEN)今天宣布，3期ECHELON-1临床试验达到主要终点，即修订版无进展生存(PFS)优于对照组，差异有统计学意义。ECHELON-1是随机、多中心试验，评估ADCETRIS (brentuximab...
View ArticleClik here to view.
Ipsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New...
PARIS & TOKYO Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, today announced that Teijin Pharma has...
View ArticleClik here to view.
Second Sight Announces Market Entry into South Korea with Two Implants and...
SYLMAR, Calif. Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision...
View ArticleClik here to view.
Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
MELBOURNE, Australia & SAN FRANCISCO Prana Biotechnology Ltd (NASDAQ: PRAN) (ASX: PBT) today announced the article “The novel compound PBT434 prevents iron-mediated neurodegeneration and...
View ArticleClik here to view.
新基公司和百济神州在免疫肿瘤领域达成全球战略合作 共同在实体肿瘤领域推进PD-1抑制剂项目
美国新泽西州萨米特及中国北京 (美国商业资讯)– 新基公司(纳斯达克股票代码:CELG) 和 百济神州有限公司(纳斯达克股票代码:BGNE)宣布达成战略合作，共同开发和商业化反程序性细胞死亡蛋白（PD-1）抑制剂...
View ArticleClik here to view.
Celgene Corporation Enters Into Global Strategic Immuno-Oncology...
SUMMIT, N.J. & BEIJING Celgene Corporation (NASDAQ:CELG) and BeiGene, Ltd. (NASDAQ:BGNE) entered into a strategic collaboration to develop and commercialize BeiGene’s investigational...
View ArticleClik here to view.
Konica Minolta to Acquire U.S.-based Ambry Genetics in a Deal Valued at US$1...
TOKYO & ALISO VIEJO, Calif. Konica Minolta, Inc. (Konica Minolta) (TOKYO: 4902) (ISIN: JP3300600008) and Ambry Genetics Corporation (Ambry) today announced the signing of a definitive agreement...
View ArticleClik here to view.
ゼブラ・メディカル・ビジョンが発展途上国20カ国で医療画像診断を改善するために初の人工知能技術を大規模導入
イスラエル・シェファイム & 印バンガロール （ビジネスワイヤ） —...
View Article